kidney disease

Showing 10 posts of 10 posts found.


Novartis acquires Chinook Therapeutics for $3.5bn

June 12, 2023
Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …

AstraZeneca drug approved by FDA for kidney disease treatment

May 4, 2021
Manufacturing and Production AstraZeneca, FDA, kidney disease, pharma, pharma news

AstraZeneca’s Farxiga drug has been approved for the treatment of chronic kidney disease (CKD) in the US by the FDA.

Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …


NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …


Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care

October 4, 2018
Research and Development Mayo Clinic, baxter, kidney disease, pharma, renal

American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a bid to establish a “renal …


J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …


SMC approves first ever treatment for genetic kidney disease

January 12, 2016
Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …


Otsuka kidney drug earns first NICE nod

October 28, 2015
Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …

Latest content